News About: Pharm. Industry
LG Life Sciences’ 2017 General Personnel Reshuffle to strengthen vaccine businessLG Life Sciences Ltd.(CEO: Il-Jae Jeong, President) held a corporate board meeting on December 2, and carried out the 2017 LG Life Sciences General Personnel Reshuffle.
Through...
|
Prosecution starts to investigate rebates on well-known pharmas, arresting hospital directors
While the major rebate cases which hit the industry this year are coming to an end, the pharmaceutical industry has paid sharp attention to investigations on influential pharmaceutical companies being conducted.
The ...
Court’s decision will become watershed to arrest Hanmi’s employees over delayed noticeIn terms of the case of Hanmi Pharm which caused short sales and delayed notice issues about its technology export, the court is about to announce the result of its investigatio...
|
Listed pharmas lowered dependency on loans, but focused on conservative management
It was observed pharmaceutical companies have reduced dependency on loans from foreign capital. Although interest rates have kept low, pharmaceutical companies are still carrying out conservative management instead of...
Dong-A Pharm’s guilt finalized for provision of largest amount of rebates in history
Dong-A Pharm was finally given a judgement of guilt for provision of the largest amount of rebates as lecture fees to doctors.
On December 1, the Supreme Court Petty Bench I(Justice Shin Kim) finalized the original r...
Increased No. of employees in listed pharmas by 1,120 people this year
This year, listed pharmaceutical companies were observed to recruit about 1,000 new employees. Moreover, 2 of 3 pharmaceutical companies were analyzed to increase the number of employees; thus, the pharmaceutical indu...
Prosecution’s active investigations on influential pharmas
While the major rebate cases which surprised the industry this year are coming to an end, the pharmaceutical industry has paid sharp attention to investigations on influential pharmaceutical companies being conducted....
Novartis, “We have no plan to compensate for the difference of Galvusmet’s dropped price”As the company announced it has no plan to compensate the difference of the decreased drug price of Galvusmet whose upper limit price will be dropped from the 1st of December, t...
|
Only 17 of them having less than 10% in foreigner-owned share ratio
There were only 17 companies whose foreigner-owned share ratio exceed 10% among listed pharmaceutical companies, and the one of Yuhan Corporation was about 30%.
According to the Yakup Shinmoon’s(www.yakup.com) analy...
Will Novartis rebate trial be prolonged?There is a high chance for the Novartis’ rebate trial to be prolonged.
On the 29th, the 5th Criminal Investigation Department at the Seoul Western District Court proceeded a tr...
|
